Lyfegen HealthTech AG, a Basel, Switzerland-based health technology company, raised CHF 2m in funding.
The additional funding, which brings total funding to CHF3m, was completed by private investors and the innovation program of one of Switzerland’s largest banks.
The new funding, combined with the seed capital raised in April 2019 and the founders’ contributions, will be used to further strengthen its market position in the U.S. as well as additional European and Latin America in the areas of oncology, rare diseases and medical devices.
Co-founded by Girisha Fernando, Michel Mohler, Nico Mros, and Leon Rebolledo, Lyfegen has developed a software solution to accelerate value-based healthcare contracting. Its patent-pending software analyses complex healthcare data sets in order to help patients access innovative therapies that focus on the healthcare outcomes that matter most to them and enable life sciences companies, healthcare payers and healthcare providers to develop and roll out digital value-based healthcare.
Some of the world’s 10-largest pharmaceutical and medical technologies companies are already employing the platform in strategic markets in Europe and South America.